PURPOSE: We performed a retrospective study of patients with diffuse pontine glioma (DPG) who suffered neuraxis metastasis (NM) and characterized the incidence, clinical features, radiologic findings, and patterns of disease dissemination. METHODS: Magnetic resonance imaging (MRI) of brain and spine was used to assess NM. Some patients also underwent magnetic resonance spectroscopy (MRS) (6 patients) and fluorodeoxyglucose positron emission tomography (FDG-PET) scans (13 patients) to further evaluate areas of metastatic disease. Three patients had histologic confirmation of disease at the site of NM. RESULTS: Between 1986 and 2003, 18 of 96 patients (17.3%) with DPG developed NM. The median age at diagnosis was 8 years (range, 4-17). All patients had adjuvant chemotherapy and/or focal radiotherapy at diagnosis. The NM occurred at a median of 15 months from diagnosis of DPG (range, 3-96). Three patterns of NM were seen on MRI of brain and spine in these patients; 8 (39%) had parenchymal (PM), 4 (22%) leptomeningeal (PM), 2 (11%) subependymal, and in 5 a combination of two or more patterns. The MRS and FDG-PET scan of suspected areas of metastatic disease was consistent with tumor in 6 of 6 and 12 of 13 patients who underwent these procedures respectively. Three patients also had histologic confirmation of malignant glioma at the site of NM. Despite salvage therapy, all 18 patients have died of disease at a median of 5 months (range, 0.5-20) from diagnosis of neuraxis spread. CONCLUSION: Our study emphasizes the need for screening patients with DPG for NM at the time of recurrence.
PURPOSE: We performed a retrospective study of patients with diffuse pontine glioma (DPG) who suffered neuraxis metastasis (NM) and characterized the incidence, clinical features, radiologic findings, and patterns of disease dissemination. METHODS: Magnetic resonance imaging (MRI) of brain and spine was used to assess NM. Some patients also underwent magnetic resonance spectroscopy (MRS) (6 patients) and fluorodeoxyglucose positron emission tomography (FDG-PET) scans (13 patients) to further evaluate areas of metastatic disease. Three patients had histologic confirmation of disease at the site of NM. RESULTS: Between 1986 and 2003, 18 of 96 patients (17.3%) with DPG developed NM. The median age at diagnosis was 8 years (range, 4-17). All patients had adjuvant chemotherapy and/or focal radiotherapy at diagnosis. The NM occurred at a median of 15 months from diagnosis of DPG (range, 3-96). Three patterns of NM were seen on MRI of brain and spine in these patients; 8 (39%) had parenchymal (PM), 4 (22%) leptomeningeal (PM), 2 (11%) subependymal, and in 5 a combination of two or more patterns. The MRS and FDG-PET scan of suspected areas of metastatic disease was consistent with tumor in 6 of 6 and 12 of 13 patients who underwent these procedures respectively. Three patients also had histologic confirmation of malignant glioma at the site of NM. Despite salvage therapy, all 18 patients have died of disease at a median of 5 months (range, 0.5-20) from diagnosis of neuraxis spread. CONCLUSION: Our study emphasizes the need for screening patients with DPG for NM at the time of recurrence.
Authors: D Zagzag; D R Friedlander; B Margolis; M Grumet; G L Semenza; H Zhong; J W Simons; J Holash; S J Wiegand; G D Yancopoulos Journal: Pediatr Neurosurg Date: 2000-07 Impact factor: 1.162
Authors: D Zagzag; D C Miller; E Knopp; J P Farmer; M Lee; S Biria; A Pellicer; F J Epstein; J C Allen Journal: Pediatrics Date: 2000-11 Impact factor: 7.124
Authors: Anne Laprie; Andrea Pirzkall; Daphne A Haas-Kogan; Soonmee Cha; Anuradha Banerjee; Terry P Le; Ying Lu; Sarah Nelson; Tracy R McKnight Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-01 Impact factor: 7.038
Authors: Sridharan Gururangan; Eugene Hwang; James E Herndon; Herbert Fuchs; Timothy George; R Edward Coleman Journal: Neurosurgery Date: 2004-12 Impact factor: 4.654
Authors: A Aria Tzika; Loukas G Astrakas; Maria K Zarifi; David Zurakowski; Tina Young Poussaint; Liliana Goumnerova; Nancy J Tarbell; Peter McL Black Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Christopher L Tinkle; Brent A Orr; John T Lucas; Paul Klimo; Zoltan Patay; Suzanne J Baker; Alberto Broniscer; Ibrahim Qaddoumi Journal: Pediatr Blood Cancer Date: 2017-01-13 Impact factor: 3.167
Authors: James L Leach; James Roebker; Austin Schafer; Joshua Baugh; Brooklyn Chaney; Christine Fuller; Maryam Fouladi; Adam Lane; Renee Doughman; Rachid Drissi; Mariko DeWire-Schottmiller; David S Ziegler; Jane E Minturn; Jordan R Hansford; Stacie S Wang; Michelle Monje-Deisseroth; Paul G Fisher; Nicholas G Gottardo; Hetal Dholaria; Roger Packer; Katherine Warren; Sarah E S Leary; Stewart Goldman; Ute Bartels; Cynthia Hawkins; Blaise V Jones Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: John Thomas Lucas; Andrew Jonathan Huang; Ryan T Mott; Glenn J Lesser; Stephen Bradley Tatter; Michael David Chan Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Chloé Louise Gelder; Cynthia Hawkins; Michal Zapotocky; Peter Dirks; Ute Bartels; Eric Bouffet Journal: Childs Nerv Syst Date: 2019-01-31 Impact factor: 1.475